GO:0141107 methyltransferase regulator activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0141107 methyltransferase regulator activity is a molecular function defined as binding to and modulating the activity of a methyltransferase.
• Regulators can act as activators, inhibitors, or targeting subunits that direct methyltransferase substrate specificity.
• Key methyltransferases under regulation include METTL3, NSUN2, and Clr4/SUV39H1, which control RNA m6A, RNA m5C, and histone H3K9 methylation, respectively.
• Dysregulation of methyltransferase regulator activity is linked to colorectal cancer, leukemia, thymic aging, and ferroptosis resistance.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect regulator function in disease.
• Understanding this activity enables therapeutic targeting of methyltransferase complexes in cancer and aging-related disorders.
Description
Methyltransferase regulator activity (GO:0141107) is a molecular function that describes proteins binding to and modulating the activity of a methyltransferase enzyme. Methyltransferases catalyze the transfer of a methyl group to substrates such as DNA, RNA, and histones, and their regulators ensure precise control of methylation marks in space and time. This activity is critical because methylation is a central epigenetic and epitranscriptomic mechanism that influences gene expression, RNA stability, and chromatin architecture. In recent years, regulators of methyltransferases have emerged as key nodes in cancer, developmental biology, and aging. For example, the m6A methyltransferase METTL3 requires regulatory partners to activate JAK1/STAT3 signaling in colorectal cancer, while NSUN2 lactylation modulates ferroptosis resistance through GCLC-dependent glutathione synthesis. Understanding GO:0141107 therefore provides a framework for studying how methylation is controlled and how its disruption contributes to disease. Researchers increasingly rely on CRISPR-based models to test whether candidate regulators causally affect methyltransferase function and downstream phenotypes.
methyltransferase regulator activity At A Glance
| GO ID | GO:0141107 |
|---|---|
| GO term | methyltransferase regulator activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binds to and modulates the activity of a methyltransferase |
| Example regulators | METTL3-associated factors, NSUN2 modulators, Clr4/SUV39H1 regulators |
| Disease relevance | Cancer, aging, ferroptosis resistance, leukemia |
| Research methods | CRISPR KO, point mutation, knock-in, overexpression, RNA-seq, proteomics |
What Is GO:0141107?
According to the Gene Ontology, GO:0141107 methyltransferase regulator activity is defined as the function of binding to and modulating the activity of a methyltransferase. This means the gene product does not necessarily catalyze methylation itself but instead influences the efficiency, specificity, or localization of a methyltransferase enzyme. Regulation can be positive or negative and may involve direct physical interaction, conformational changes, or recruitment of additional cofactors.
Why Is methyltransferase regulator activity Important in Cell Biology?
Methyltransferase regulator activity is important because it provides a layer of control over methylation-dependent processes that are fundamental to gene regulation, RNA fate, and chromatin structure. Without regulators, methyltransferases could act promiscuously or at the wrong time, leading to aberrant methylation patterns associated with cancer, developmental defects, and aging. For instance, METTL3-mediated m6A modification requires regulatory interactions to promote stress granule phase separation during senescence and to maintain chromatin TAD integrity in MLLr+ AML. Thus, studying GO:0141107 helps explain how methylation is directed and how its misregulation drives disease.
• Controls epitranscriptomic marks such as m6A and m5C that affect RNA stability and translation.
• Regulates histone methylation and heterochromatin formation through factors like Clr4/SUV39H1.
• Modulates cancer progression via JAK1/STAT3 signaling in colorectal cancer.
• Influences ferroptosis resistance through NSUN2-dependent glutathione synthesis.
• Governs thymocyte development and thymic involution by regulating ferroptosis.
• Promotes stress granule phase separation during senescence via METTL3.
• Maintains chromatin TAD integrity in MLLr+ AML through the METTL3-YTHDC1 axis.
• Provides therapeutic targets for methyltransferase-related cancers.
• Enables precise CRISPR-based dissection of methylation regulatory networks.
• Links metabolic reprogramming to epigenetic regulation in aging and disease.
Molecular Mechanism of methyltransferase regulator activity
Binding to the methyltransferase
In simple terms: The regulator physically attaches to the methyltransferase enzyme.
Regulators of methyltransferases typically initiate their function by direct binding to the enzyme, which can occur through conserved domains or unstructured regions. This interaction may stabilize the methyltransferase, alter its conformation, or recruit it to specific substrates. For example, METTL3 functions within a complex where regulatory subunits influence its m6A deposition on RNA.
Modulation of catalytic activity
In simple terms: The regulator can turn the methyltransferase up or down.
Once bound, the regulator can enhance or inhibit the methyltransferase catalytic activity. This modulation may involve allosteric changes, competition with cofactors such as S-adenosylmethionine, or presentation of the substrate. In cancer, METTL3 activity is modulated to activate JAK1/STAT3 signaling, demonstrating how regulator activity can drive oncogenic pathways.
Substrate targeting and specificity
In simple terms: The regulator helps the methyltransferase choose what to methylate.
Many regulators act as targeting subunits that direct the methyltransferase to specific RNA or histone substrates. For instance, NSUN2 lactylation enhances GCLC-dependent glutathione synthesis, linking metabolic state to RNA methylation targeting. Similarly, Clr4/SUV39H1 ubiquitination and non-coding RNA mediate transcriptional silencing via Swi6 phase separation, illustrating how regulators specify histone methylation sites.
Integration with cellular signaling
In simple terms: The regulator connects methylation to outside signals.
Methyltransferase regulator activity is often downstream of signaling pathways such as JAK/STAT or metabolic cues. METTL3 promotes colorectal cancer progression through activating JAK1/STAT3 signaling, showing that regulator activity can be embedded in oncogenic signaling loops. In senescence, METTL3-mediated chromatin contacts promote stress granule phase separation through metabolic reprogramming, further highlighting signal integration.
Phase separation and chromatin architecture
In simple terms: Regulators can help form membrane-less compartments and organize chromatin.
Emerging evidence indicates that methyltransferase regulators participate in phase separation and chromatin organization. The METTL3-YTHDC1 axis mediates architectural RNA m6A modification to modulate chromatin TAD integrity in MLLr+ AML. Clr4/SUV39H1 regulation involves Swi6 phase separation for heterochromatin silencing. These mechanisms expand the functional repertoire of GO:0141107 beyond simple enzyme modulation.
Key Genes Involved in GO:0141107 methyltransferase regulator activity
The following genes and proteins represent key examples of methyltransferase regulators or methyltransferases whose activity is modulated in the context of GO:0141107.
| Gene | Major Role | Research Relevance |
|---|---|---|
| METTL3 | m6A methyltransferase; regulated in cancer and aging | Promotes colorectal cancer via JAK1/STAT3; governs thymocyte development; stress granule phase separation |
| NSUN2 | RNA m5C methyltransferase; regulated by lactylation | Drives ferroptosis resistance through GCLC-dependent glutathione synthesis |
| Clr4/SUV39H1 | Histone H3K9 methyltransferase; regulated by ubiquitination | Mediates heterochromatin silencing via Swi6 phase separation |
| YTHDC1 | m6A reader; interacts with METTL3 axis | Modulates chromatin TAD integrity in MLLr+ AML |
| JAK1 | Signaling kinase downstream of METTL3 | Activated in colorectal cancer progression |
| STAT3 | Transcription factor downstream of JAK1 | Mediates METTL3-driven colorectal cancer progression |
| GCLC | Glutathione synthesis enzyme | Regulated by NSUN2 lactylation to control ferroptosis |
| Swi6 | Heterochromatin protein | Phase separation mediator in Clr4/SUV39H1 pathway |
| METTL14 | Component of m6A methyltransferase complex | Potential regulatory subunit for METTL3 activity |
| WTAP | m6A methyltransferase complex adaptor | Regulates METTL3 localization and activity |
| FTO | m6A demethylase | Opposes METTL3 function; potential regulator target |
| ALKBH5 | m6A demethylase | Balances m6A methylation; relevant to regulator studies |
| DNMT1 | DNA methyltransferase | Regulated by factors affecting DNA methylation |
| DNMT3A | DNA methyltransferase | De novo methylation; subject to regulator activity |
| EZH2 | Histone H3K27 methyltransferase | Regulated in cancer; target for therapeutic intervention |
| SETD2 | Histone H3K36 methyltransferase | Regulated in leukemia and solid tumors |
How Is methyltransferase regulator activity Regulated?
Methyltransferase regulator activity is itself regulated at multiple levels. Post-translational modifications such as lactylation can directly modify regulators; NSUN2 lactylation drives cancer cell resistance to ferroptosis through enhancing GCLC-dependent glutathione synthesis. Ubiquitination of Clr4/SUV39H1 regulates heterochromatin silencing via Swi6 phase separation. Metabolic reprogramming during senescence influences METTL3-mediated chromatin contacts and stress granule phase separation. Additionally, signaling pathways like JAK1/STAT3 are activated by METTL3 in colorectal cancer, indicating feedback between methylation regulators and oncogenic signaling. These layers of regulation ensure that methyltransferase activity is tightly coupled to cellular state.
methyltransferase regulator activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| METTL3 | Colorectal cancer; thymic involution | Knockout and overexpression in cancer cell lines; mouse models |
| NSUN2 | Ferroptosis resistance in cancer | Point mutation of lactylation sites; knockout in cancer cells |
| Clr4/SUV39H1 | Heterochromatin silencing; cancer | Knock-in of ubiquitination-deficient mutants; phase separation assays |
| METTL3-YTHDC1 | MLLr+ AML; chromatin TAD integrity | Knockout and tagged knock-in in leukemia cell lines |
| JAK1/STAT3 | Colorectal cancer progression | Overexpression and knockout in colorectal cancer models |
Colorectal cancer
METTL3 promotes colorectal cancer progression through activating JAK1/STAT3 signaling pathway. This demonstrates that methyltransferase regulator activity can drive oncogenic signaling and supports targeting METTL3 or its regulators in colorectal cancer.
Ferroptosis resistance in cancer
NSUN2 lactylation drives cancer cell resistance to ferroptosis through enhancing GCLC-dependent glutathione synthesis. This links methyltransferase regulator activity to metabolic reprogramming and cell death evasion, suggesting therapeutic strategies to overcome ferroptosis resistance.
Thymic aging and immune development
METTL3 governs thymocyte development and thymic involution by regulating ferroptosis. This implicates m6A methyltransferase regulation in age-related immune decline and provides a model for studying GO:0141107 in aging.
Leukemia and chromatin architecture
The METTL3-YTHDC1 axis mediates architectural RNA m6A modification to modulate the integrity of chromatin TADs in MLLr+ AML genome. Disruption of this regulatory axis may contribute to leukemogenesis through altered chromatin topology.
From methyltransferase regulator activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate regulator bind and modulate METTL3? | Knockout of regulator followed by co-immunoprecipitation and m6A dot blot |
| Does a specific point mutation in NSUN2 affect ferroptosis? | Point mutation knock-in of lactylation site in cancer cells |
| How does Clr4/SUV39H1 ubiquitination affect heterochromatin? | Knock-in of ubiquitin-deficient Clr4 mutant; Swi6 phase separation imaging |
| What is the role of METTL3 in thymocyte development? | Conditional knockout mouse models and thymic organ cultures |
| Does METTL3-YTHDC1 axis control chromatin TADs? | Tagged knock-in of METTL3 and YTHDC1; Hi-C and ChIP-seq |
| Can overexpression of a regulator drive cancer? | Overexpression of METTL3 or NSUN2 in cell lines and xenografts |
How to Study the methyltransferase regulator activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on methylation | Identify novel regulators of METTL3 |
| MeRIP-seq | m6A methylation sites and abundance | Assess METTL3 regulator impact on epitranscriptome |
| Co-immunoprecipitation | Protein-protein interactions | Confirm binding of regulator to methyltransferase |
| FRAP | Phase separation dynamics | Study Swi6 condensation in heterochromatin |
| Hi-C | Chromatin topology | Evaluate TAD integrity in MLLr+ AML |
| Western blot | Protein expression and modification | Detect NSUN2 lactylation and GCLC levels |
| Flow cytometry | Cell death and ferroptosis | Measure ferroptosis resistance upon NSUN2 mutation |
| RNA-seq | Transcriptome changes | Profile gene expression after regulator knockout |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify regulators of methyltransferase activity by selecting for changes in methylation marks or downstream phenotypes. For example, knocking out candidate genes followed by m6A quantification can reveal essential regulators of METTL3.
Point mutation and knock-in models
Point mutations in regulatory domains or post-translational modification sites can dissect specific functions. NSUN2 lactylation site mutations can test effects on ferroptosis resistance, while Clr4 ubiquitination mutants reveal heterochromatin silencing mechanisms.
RNA-seq and m6A mapping
RNA sequencing and m6A-specific mapping (MeRIP-seq) measure how regulator perturbation alters transcript abundance and methylation patterns. This is critical for linking GO:0141107 to epitranscriptomic outcomes.
Proteomics and interactomics
Affinity purification coupled with mass spectrometry can identify proteins that bind methyltransferases, directly defining regulators under GO:0141107. Proximity labeling can capture transient interactions in living cells.
Imaging and phase separation assays
Fluorescence microscopy and FRAP can assess phase separation of regulators such as Swi6 in heterochromatin and stress granule formation driven by METTL3. These methods visualize the spatial organization of methyltransferase regulation.
How CRISPR Can Be Used to Study GO:0141107 methyltransferase regulator activity
Knockout
CRISPR knockout of candidate regulator genes is used to test loss-of-function effects on methyltransferase activity and downstream phenotypes. For example, knocking out METTL3 reduces m6A levels and inhibits colorectal cancer progression. Knockout of NSUN2 sensitizes cancer cells to ferroptosis.
Point Mutation
Point mutations can be introduced to ablate specific regulatory sites, such as lactylation or ubiquitination sites. NSUN2 lactylation site mutants reveal effects on GCLC-dependent glutathione synthesis. Clr4 ubiquitination mutants show impaired heterochromatin silencing.
Knock-in
Knock-in of tagged or mutant versions of methyltransferases and regulators allows tracking and functional studies. Tagged METTL3 and YTHDC1 knock-in enables chromatin TAD analysis in leukemia cells. Knock-in of Swi6 fusion proteins helps visualize phase separation.
Overexpression
Overexpression of methyltransferase regulators can drive oncogenic phenotypes. Overexpression of METTL3 promotes colorectal cancer progression via JAK1/STAT3. Overexpression of NSUN2 increases ferroptosis resistance.
How EDITGENE Supports methyltransferase regulator activity Research
Researchers studying methyltransferase regulator activity-related genes often need to determine whether a candidate gene is causally involved in methylation control, disease progression, or therapeutic response. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for methyltransferase regulator activity research.
Frequently Asked Questions About methyltransferase regulator activity
What is GO:0141107 methyltransferase regulator activity?
It is a molecular function defined as binding to and modulating the activity of a methyltransferase.
What genes are involved in methyltransferase regulator activity?
Key genes include METTL3, NSUN2, Clr4/SUV39H1, YTHDC1, and their regulatory partners.
How does methyltransferase regulator activity affect cancer?
It can drive oncogenic signaling, as METTL3 promotes colorectal cancer through JAK1/STAT3, and NSUN2 lactylation confers ferroptosis resistance.
What diseases are linked to methyltransferase regulator activity?
Colorectal cancer, leukemia, thymic aging, and ferroptosis-resistant cancers are linked to this activity.
How can I study methyltransferase regulator activity?
CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, MeRIP-seq, and proteomics are common approaches.
What is the role of METTL3 in methyltransferase regulator activity?
METTL3 is an m6A methyltransferase whose activity is modulated by regulators and is critical in cancer, aging, and chromatin organization.
How does NSUN2 lactylation regulate ferroptosis?
NSUN2 lactylation enhances GCLC-dependent glutathione synthesis, leading to ferroptosis resistance in cancer cells.
What is the connection between Clr4/SUV39H1 and heterochromatin?
Clr4/SUV39H1 ubiquitination and non-coding RNA mediate transcriptional silencing via Swi6 phase separation.
Can CRISPR screens identify new methyltransferase regulators?
Yes, genome-wide CRISPR knockout screens can uncover regulators of methyltransferase activity and methylation marks.
What services does EDITGENE offer for methyltransferase regulator research?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics.
Conclusion
Methyltransferase regulator activity (GO:0141107) is a fundamental molecular function that controls the when, where, and how of methylation. Through regulators such as METTL3, NSUN2, and Clr4/SUV39H1, cells fine-tune epitranscriptomic and epigenetic marks that impact cancer, aging, and development. Continued research using CRISPR models and multi-omics will reveal new therapeutic opportunities. EDITGENE supports these efforts with end-to-end cell model and screening services.
References
- 1. Sun Y et al.. 2023. METTL3 promotes colorectal cancer progression through activating JAK1/STAT3 signaling pathway.. Cell Death Dis 14(11):765 PMID: 38001065
- 2. He PC et al.. 2021. m(6) A RNA methylation: from mechanisms to therapeutic potential.. EMBO J 40(3):e105977 PMID: 33470439
- 3. Niu K et al.. 2025. NSUN2 lactylation drives cancer cell resistance to ferroptosis through enhancing GCLC-dependent glutathione synthesis.. Redox Biol 79:103479 PMID: 39742570
- 4. Qi YN et al.. 2023. Methyltransferase-like proteins in cancer biology and potential therapeutic targeting.. J Hematol Oncol 16(1):89 PMID: 37533128
- 5. Jing H et al.. 2024. METTL3 governs thymocyte development and thymic involution by regulating ferroptosis.. Nat Aging 4(12):1813-1827 PMID: 39443728
- 6. Kim HS et al.. 2024. Clr4(SUV39H1) ubiquitination and non-coding RNA mediate transcriptional silencing of heterochromatin via Swi6 phase separation.. Nat Commun 15(1):9384 PMID: 39477922
- 7. Wang C et al.. 2024. METTL3-mediated chromatin contacts promote stress granule phase separation through metabolic reprogramming during senescence.. Nat Commun 15(1):5410 PMID: 38926365
- 8. Fu R et al.. 2025. The METTL3-YTHDC1 axis mediates architectural RNA m(6)A modification to modulate the integrity of chromatin TADs in MLLr + AML genome.. Mol Cancer 25(1):22 PMID: 41430607
